HUP0203582A2 - Polymorphic n-[3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl]-4-nitro benzamide hydrochloride, process for its preparation, pharmaceutical composition comprising thereof and its use - Google Patents
Polymorphic n-[3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl]-4-nitro benzamide hydrochloride, process for its preparation, pharmaceutical composition comprising thereof and its use Download PDFInfo
- Publication number
- HUP0203582A2 HUP0203582A2 HU0203582A HUP0203582A HUP0203582A2 HU P0203582 A2 HUP0203582 A2 HU P0203582A2 HU 0203582 A HU0203582 A HU 0203582A HU P0203582 A HUP0203582 A HU P0203582A HU P0203582 A2 HUP0203582 A2 HU P0203582A2
- Authority
- HU
- Hungary
- Prior art keywords
- polymorphic form
- propyl
- ethyl
- amino
- dimethoxyphenyl
- Prior art date
Links
- QLUVAVFNMRXIIZ-UHFFFAOYSA-N n-[3-[2-(3,4-dimethoxyphenyl)ethylamino]propyl]-4-nitrobenzamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNCCCNC(=O)C1=CC=C([N+]([O-])=O)C=C1 QLUVAVFNMRXIIZ-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 8
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 19
- 230000000302 ischemic effect Effects 0.000 claims abstract description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 12
- 230000006793 arrhythmia Effects 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002329 infrared spectrum Methods 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 3
- 239000012467 final product Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000033764 rhythmic process Effects 0.000 abstract description 2
- -1 N-[3-{[2-(3,4-dimethoxyphenyl)ethyl]-amino}-propyl]-4-nitrobenzamide hydrochloride acetonitrile Chemical compound 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 28
- 239000000203 mixture Substances 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical group CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001160 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9923933.7A GB9923933D0 (en) | 1999-10-08 | 1999-10-08 | Novel pharmaceutical |
| PCT/GB2000/003847 WO2001027071A1 (en) | 1999-10-08 | 2000-10-06 | Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0203582A2 true HUP0203582A2 (en) | 2004-03-01 |
Family
ID=10862442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203582A HUP0203582A2 (en) | 1999-10-08 | 2000-10-06 | Polymorphic n-[3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl]-4-nitro benzamide hydrochloride, process for its preparation, pharmaceutical composition comprising thereof and its use |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1218334A1 (cs) |
| JP (1) | JP2003511437A (cs) |
| KR (1) | KR20020043618A (cs) |
| CN (1) | CN1384817A (cs) |
| AU (1) | AU7546000A (cs) |
| BR (1) | BR0014591A (cs) |
| CA (1) | CA2386845A1 (cs) |
| CZ (1) | CZ20021189A3 (cs) |
| GB (1) | GB9923933D0 (cs) |
| HK (1) | HK1049147A1 (cs) |
| HU (1) | HUP0203582A2 (cs) |
| IL (1) | IL148966A0 (cs) |
| MX (1) | MXPA02003516A (cs) |
| NO (1) | NO20021639L (cs) |
| PL (1) | PL354137A1 (cs) |
| TR (1) | TR200200949T2 (cs) |
| WO (1) | WO2001027071A1 (cs) |
| ZA (1) | ZA200202679B (cs) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2412306T3 (es) * | 2002-01-09 | 2013-07-11 | Emisphere Technologies, Inc. | Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio |
| CN103923169B (zh) * | 2006-12-06 | 2017-05-24 | 科内图斯医药公司 | (3s)‑3‑[n‑(n’‑(2‑叔丁基苯基)草氨酰基)丙氨酰基]氨基‑5‑(2’,3’,5’,6’‑四氟苯氧基)‑4‑氧代戊酸的结晶形式 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2726267B1 (fr) * | 1994-10-26 | 1998-01-02 | Smithkline Beecham Lab | Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer |
| GB9706376D0 (en) * | 1997-03-27 | 1997-05-14 | Smithkline Beecham Plc | Novel pharmaceutical |
-
1999
- 1999-10-08 GB GBGB9923933.7A patent/GB9923933D0/en not_active Ceased
-
2000
- 2000-10-06 HU HU0203582A patent/HUP0203582A2/hu unknown
- 2000-10-06 CA CA002386845A patent/CA2386845A1/en not_active Abandoned
- 2000-10-06 BR BR0014591-2A patent/BR0014591A/pt not_active Application Discontinuation
- 2000-10-06 TR TR2002/00949T patent/TR200200949T2/xx unknown
- 2000-10-06 KR KR1020027004451A patent/KR20020043618A/ko not_active Withdrawn
- 2000-10-06 MX MXPA02003516A patent/MXPA02003516A/es unknown
- 2000-10-06 CZ CZ20021189A patent/CZ20021189A3/cs unknown
- 2000-10-06 WO PCT/GB2000/003847 patent/WO2001027071A1/en active IP Right Grant
- 2000-10-06 HK HK02109370.9A patent/HK1049147A1/zh unknown
- 2000-10-06 EP EP00964535A patent/EP1218334A1/en not_active Withdrawn
- 2000-10-06 CN CN00813990A patent/CN1384817A/zh active Pending
- 2000-10-06 AU AU75460/00A patent/AU7546000A/en not_active Abandoned
- 2000-10-06 PL PL00354137A patent/PL354137A1/xx not_active Application Discontinuation
- 2000-10-06 JP JP2001530092A patent/JP2003511437A/ja active Pending
- 2000-10-06 IL IL14896600A patent/IL148966A0/xx unknown
-
2002
- 2002-04-05 NO NO20021639A patent/NO20021639L/no not_active Application Discontinuation
- 2002-04-05 ZA ZA200202679A patent/ZA200202679B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20021639D0 (no) | 2002-04-05 |
| BR0014591A (pt) | 2002-06-11 |
| PL354137A1 (en) | 2003-12-29 |
| TR200200949T2 (tr) | 2002-08-21 |
| ZA200202679B (en) | 2003-05-28 |
| EP1218334A1 (en) | 2002-07-03 |
| NO20021639L (no) | 2002-05-30 |
| KR20020043618A (ko) | 2002-06-10 |
| CN1384817A (zh) | 2002-12-11 |
| GB9923933D0 (en) | 1999-12-08 |
| AU7546000A (en) | 2001-04-23 |
| CZ20021189A3 (cs) | 2002-09-11 |
| MXPA02003516A (es) | 2004-09-10 |
| IL148966A0 (en) | 2002-11-10 |
| HK1049147A1 (zh) | 2003-05-02 |
| JP2003511437A (ja) | 2003-03-25 |
| CA2386845A1 (en) | 2001-04-19 |
| WO2001027071A1 (en) | 2001-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007112796A (ja) | 塩酸イバブラジンのδ結晶形態、その製造法、およびそれを含有する医薬組成物 | |
| RU2159227C2 (ru) | Нитробензамиды, фармацевтическая композиция, способ ее получения и способ лечения и/или профилактики аритмий и ишемических нарушений ритма | |
| HUP0203582A2 (en) | Polymorphic n-[3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl]-4-nitro benzamide hydrochloride, process for its preparation, pharmaceutical composition comprising thereof and its use | |
| HUP0001683A2 (hu) | Antiaritmiás szerként felhasználható hidratált nitro-benzamid | |
| US4814330A (en) | 3-phenyl-1-propanones, process of preparing thereof and method of treating arrhythmias | |
| EP1218335A1 (en) | Hydrated n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride and it's use in pharmaceutical compositions | |
| JPH02218653A (ja) | インダンから誘導される化合物の薬剤としての使用並びにそれらを含有する製薬組成物 | |
| EP0719263B1 (en) | Heterocyclic carboxamide derivatives with antiarrhythmic activity | |
| US20010056207A1 (en) | Nitro-benzamide useful as anti-arrhythmic agent | |
| HU181774B (en) | Process for preparing 1-amino-2-propanol derivatives | |
| US4992446A (en) | Tricyclic quinolizine amides | |
| HK1025089B (en) | Nitro-benzamide useful as anti-arrhythmic agent | |
| CZ341899A3 (cs) | Nitrobenzamid vhodný jako antiarytmický přípravek | |
| JP3001975B2 (ja) | 結晶性チアガビン塩酸塩−水和物、その製造方法および用途 | |
| MXPA99008872A (en) | Nitro-benzamide useful as anti-arrhythmic agent | |
| WO1996027595A1 (en) | Heterocyclycarboxamides and other compounds for the treatment of the cardiac arrhythmias | |
| HU183292B (en) | Process for producing pyrrol-derivatives of myocardium-protecting, antiarrhythmic and thromaocite-aggregation-inhibiting activity and pharmaceutical compositions containing them as active agents |